Skip to main content
Premium Trial:

Request an Annual Quote

Phenomenome, Polymedco Ink Pact to Commercialize Mass Spec-based Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Phenomenome Discoveries has granted Polymedco Cancer Diagnostic Products a license to commercialize Phenomenome's mass spectrometry-based blood test for colorectal cancer in the US.

The test uses triple quadrupole mass spec technology to detect a deficiency in novel anti-cancer and anti-inflammatory metabolites in a blood sample, which Phenomenome said it has discovered occurs in nine out of 10 patients with colorectal cancer.

Dayan Goodenowe, president and CEO of Phenomenome, said in a statement that the two firms submitted an application with the US Food and Drug Administration last month for premarket review, "and we look forward to receiving approval and moving ahead with our shared commercialization strategy."

Financial and other terms of the deal were not disclosed.

Based in Saskatoon, Saskatchewan, Phenomenome discovers and develops biomarkers for cancer and neurodegenerative disorders. Polymedco is headquartered in Cortlandt Manor, NY, and manufactures, markets, and distributes clinical diagnostic kits and devices in the area of oncology.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.